이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

S2Medical 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Petter Sivlér

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	11.4yrs
CEO 소유권	0.001%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.5yrs

최근 관리 업데이트

Recent updates

CEO

Petter Sivlér (39 yo)

11.4yrs

테뉴어

Mr. Petter Sivlér Co-Founded S2Medical AB (publ) and has been its Chief Executive Officer from 2013.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mårten Skog	Co-Founder	11.4yrs	데이터 없음	데이터 없음
Fredrik Skog	Chair of the Board	2.5yrs	데이터 없음	0.0098% SEK 111.1
Miles Wright	Director	2.5yrs	데이터 없음	데이터 없음
Chadi Asaad	Director	2.5yrs	데이터 없음	데이터 없음
Patrick Sheehan	Director	2.5yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

경험이 풍부한 이사회: S21 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

S2Medical 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

No independent directors

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

No independent directors

Recent updates

First quarter 2024 earnings released

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: kr0.082 loss per share (vs kr1.24 loss in FY 2022)

New major risk - Shareholder dilution

Third quarter 2023 earnings released

Second quarter 2023 earnings released

S2Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

New major risk - Shareholder dilution

First quarter 2023 earnings released

Full year 2022 earnings released: kr1.15 loss per share (vs kr1.35 loss in FY 2021)

S2Medical AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

S2Medical AB (publ) Announces the Positive Outcome of Antimicrobial Peptides Tests Against the Multi Resistant Bacteria

No independent directors

Third quarter 2022 earnings released

EPO Announces Intention to Approve Patenting of S2Medical AB's AMP Technology

S2Medical AB Announces Positive outcome from evaluation of Epiprotect in Saudi Arabia

S2Medical AB (publ) Updates Instagraft-Patent Approval in Israel

S2Medical AB (publ) Receives the Response from the European Patent Office That They Intend to Grant Patent Protection for the Company's Instagraft Technology Within Around Forty European Countries

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released

First quarter 2021 earnings released

New 90-day low: €0.69

New 90-day low: €0.76

S2Medical AB (publ) (OM:S2M) entered into an agreement to acquire Curenc AB.

New 90-day high: €0.90

Earnings released

New 90-day high - €0.86

CEO

테뉴어

이사회 구성원

평균 재임 기간